LINC00460 and central nervous system cancer: In addition, upregulation of LINC00460 was also associated with poor progression free survival (PFS) in AML [36], colorectal cancer [20, 23, 24], gastric cancer [26, 27], glioma [37], hepatocellular carcinoma [45] and lung adenocarcinoma [51] and osteosarcoma [54].